{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-088454","form_type":"8-K","ticker":null,"cik":"0001538210","company_name":"NexImmune, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.892549+00:00","generated_at":"2026-06-04T01:47:48.670351+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NexImmune CFO Timothy Stover resigns; Albert Marchio named interim CFO","bullets":["Timothy Stover, principal financial and accounting officer, resigns effective April 16, 2024; not due to disagreement.","Albert N. Marchio II appointed Interim CFO and principal financial/accounting officer, effective upon Stover's resignation.","Marchio, 71, has 32 years pharma industry experience; currently a consultant via Danforth Advisors LLC.","Danforth Advisors will provide interim CFO services under a consulting agreement with hourly rate and indemnification terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-088454","json":"https://secwatch.observer/filing/0001193125-24-088454.json","markdown":"https://secwatch.observer/filing/0001193125-24-088454.md","text":"https://secwatch.observer/filing/0001193125-24-088454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/d818104d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:47:48.670351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cb12dee2c","claim":"Albert N. Marchio II was appointed as Interim Chief Financial Officer at NexImmune, Inc..","evidence_excerpt":"On April 5, 2024, the Board of Directors of the Company appointed Albert N. Marchio II as Interim Chief Financial Officer and designated him to serve as the principal financial officer and principal accounting officer of the Company effective upon Mr. Stover’s resignation (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cc74253dac","claim":"Timothy Stover resigned as Vice President, Corporate Controller and principal financial officer and principal accounting officer at NexImmune, Inc..","evidence_excerpt":"On April 1, 2024, Timothy Stover, Vice President, Corporate Controller and the principal financial officer and principal accounting officer of NexImmune, Inc. (the “Company”), notified the Company of his intention to resign from all positions he holds at the Company, effective on April 16, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President, Corporate Controller and principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}